4月17日，据CDE官网消息，信达生物医药科技（杭州）有限公司联合申请药品“IBI3020”，获得临床试验默示许可，受理号CXSL2500123。
公示信息显示，药品“IBI3020”适应症：不可切除、局部晚期或转移性实体瘤。
信达生物医药科技（杭州）有限公司，成立于2024年，位于杭州市，是一家以从事研究和试验发展为主的企业。企业注册资本70万美元。
通过天眼查大数据分析，信达生物医药科技（杭州）有限公司专利信息3条。
主要股东信息显示，信达生物医药科技（杭州）有限公司由Innovent Biologics (HK) Limited持股100%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.